Metabolomic Profiling of Novel Mediators of Vascular Function
| Status: | Terminated |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/6/2017 |
| Start Date: | May 2007 |
| End Date: | February 2018 |
The purpose of this study is to identify and characterize specific chemicals and metabolic
pathways that change with forearm ischemia. These changes will be compared with forearm blood
flow and flow-mediated vasodilation of the brachial artery.
pathways that change with forearm ischemia. These changes will be compared with forearm blood
flow and flow-mediated vasodilation of the brachial artery.
Inclusion Criteria:
- Adults age 18 or older
- Type 2 diabetes mellitus
Exclusion Criteria:
- Type 1 diabetes mellitus
- Type 2 diabetics taking insulin, thiazolidinediones (rosiglitazone or pioglitazone),
an amylin analog (Symlin [pramlintide]), or incretin mimetics (Byetta [exenatide])
- Pregnancy
- Uncontrolled hypertension, > 180/100 mmHg
We found this trial at
1
site
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
